All In Biotech

Drug Trial Radar · NCT04471064

A Study of XY0206 Tablets in Patients With Relapsed / Refractory Acute Myeloid Leukemia

A Multicenter, Open, Dose Increasing Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Primary Efficacy of xy0206 Tablets in Relapsed / Refractory Acute Myeloid Leukemia Subjects

Last checked: Nov 19, 2026Latest source record: May 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Sep 15, 2020

Primary completion

Feb 2024

Study completion Feb 2024

Sponsor

Sponsor type
Industry
Collaborators
Proswell Medical Corporation
First posted
Jul 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. To evaluate the safety and tolerability of xy0206 as single drug in the treatment of relapsed / refractory AML; 2. Evaluate the dose limited toxicity (DLT) and maximum tolerable dose (MTD) of xy0206 as single drug in the treatment of relapsed / refractory AML subjects. 3. To evaluate the pharmacokinetic (PK), pharmacokinetic (PD) characteristics and PK / PD correlation of xy0206 as single drug treatment in relapsed / refractory AML subjects; 4. To evaluate the primary efficacy of xy0206 as single drug in the treatment of relapsed / refractory AML patients; 5. To evaluate biomarkers of xy0206 as single drug treatment for relapsed / refractory AML subjects.

Conditions

  • Acute Myeloid Leukemia

Interventions

  • XY0206Drug

    Dosage form:Tablet;Multiple dose phase:Take the medicine once a day,1 tablet at a time.4 weeks of continuous medication is one course of treatment. After the first course of treatment, the subjects can continue to receive the experimental drug treatment until they meet the withdrawal criteria. The duration and interval of treatment were determined according to the accumulated condition after multiple dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerable doseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  2. Dose limiting toxicityTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  3. Adverse eventTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  4. Adverse drug reactionsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  5. Serious adverse eventsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  6. Blood routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  7. Urine routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  8. Stool routineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  9. Blood biochemistryTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  10. Serum amylase / lipaseTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  11. Coagulation functionTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  12. ECGTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  13. EchocardiographyTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  14. Imaging examinationTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  15. Body temperatureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  16. Blood pressureTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  17. Heart rateTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  18. BreathingTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  19. SkinTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  20. HeadTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  21. NeckTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  22. ChestTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  23. AbdomenTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  24. LimbsTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  25. NervesTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication
  26. Back/spineTime frame: from the start of the medication to the end of the study or 28 days after cessation of medication

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology, Chinese Academy of Medical Sciences

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.